TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease

  • Collaboration with Biogen will leverage TRIMTECH’s proprietary TRIM21-based targeted protein degradation technology to develop novel protein degrading therapeutics for neurodegenerative diseases.
  • Includes up to $32 million in upfront and research milestone payments, with total potential payments of up to $411 million, plus royalties.

Cambridge, UK, 16 November 2026: TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has entered into a strategic research collaboration, option, and license agreement with Biogen International GmbH.

Under the terms of the agreement, Biogen and TRIMTECH will work collaboratively to discover and develop small molecule protein degraders for the treatment of neurodegenerative diseases. Upon Biogen’s exercise of the option, the company will be granted a global exclusive license to the degraders developed and will be responsible for further development and commercialisation activities. Under the terms of the agreement, TRIMTECH is eligible to receive up to $32 million in upfront and research milestone payments, with total potential payments of up to $411 million, plus royalties.

Dr Nicki Thompson, CEO, TRIMTECH Therapeutics, said: “We are excited to enter this strategic collaboration with Biogen, which is a major milestone for TRIMTECH. This is a significant validation of the progress we have made and the potential of our TRIM21-based targeted protein degradation platforms. Combining our expertise with Biogen’s strong legacy and experience in developing treatments for neurodegenerative diseases brings new promise to the potential of delivering more effective therapies for patients.”

Founded on decades of pioneering academic research into the protein TRIM21, a novel E3-ligase, TRIMTECH has demonstrated its small molecule TRIMTAC® and TRIMGLUE® degraders can access the CNS and selectively degrade toxic protein aggregates and oligomers underpinning many neurodegenerative diseases. This opens-up much needed small molecule treatment options and offers the potential to transform the course of treatment for the millions of patients battling these diseases.

ENDS

Contact:

Zyme Communications
Katie Odgaard
Katie.odgaard@zymecommunications.com

About TRIMTECH Therapeutics Ltd.
TRIMTECH Therapeutics is creating novel, highly selective, small molecule targeted protein degraders, to combat neurodegenerative and inflammatory diseases. Founded on decades of pioneering academic research into the protein TRIM21, a novel E3-ligase, the Company has demonstrated its ‘TRIMTAC’ degraders can recapitulate degradation seen with other modalities (vectors and antibodies) whilst leaving the functional monomeric form of the target protein intact and able to support healthy cellular function. TRIMTECH’s approach opens up much needed small molecule approaches for indications that affect very large populations, such as Alzheimer’s disease.

TRIMTECH was founded in 2023 by its academic co-founders Leo James, PhD FRS (MRC Laboratory of Molecular Biology) and Will McEwan, PhD (UK Dementia Research Institute, University of Cambridge), with Cambridge Innovation Capital (CIC) and SV Health Investors’ Dementia Discovery Fund (DDF) in conjunction with their joint entrepreneur-in-residence, Dr Damian Crowther.

TRIMTECH is led by a highly experienced team with vast expertise in targeted protein degradation (TPD). In 2025, the Company announced its $31 million (£25 million) seed funding round, led by CIC and DDF, with M Ventures and Pfizer Ventures joining. Additional investors also include Eli Lilly and Company, MP Healthcare Venture Management (MPH), Cambridge Enterprise Ventures, and Start Codon. This seed funding was increased to $47 million (£35 million) with an additional $14M secured in 2026. This additional financing was led by Johnson & Johnson’s corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., and BGF, who joined the existing investors.

For more information, visit: www.trimtechtherapeutics.com. Find TRIMTECH on LinkedIn and Bluesky.